<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32042967</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Coumarin: An emerging antiviral agent.</ArticleTitle><Pagination><StartPage>e03217</StartPage><MedlinePgn>e03217</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e03217</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2020.e03217</ELocationID><Abstract><AbstractText>Viral infections are responsible for many illnesses, and recent outbreaks have raised public health concerns. Despite the availability of many antiviral drugs, they are often unsuccessful due to the generation of viral mutants and less effective against their target virus. Identifying novel antiviral drugs is therefore of critical importance and natural products are an excellent source for such discoveries. Coumarin is one such natural compound that is a potential drug candidate owing to its properties of stability, solubility, and low toxicity. There are numerous evidences showing its inhibitory role against infection of various viruses such as HIV, Influenza, Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16). The mechanisms involve either inhibition of proteins essential for viral entry, replication and infection or regulation of cellular pathways such as Akt-Mtor (mammalian target of rapamycin), NF-&#x3ba;B (nuclear factor kappa-light-chain-enhancer of activated B cells), and anti-oxidative pathway including NrF-2 (The nuclear factor erythroid 2 (NFE2)-related factor 2). This review summarizes the present state of understanding with a focus on coumarin's antiviral effect and their possible molecular mechanisms against Influenza virus, HIV, Hepatitis virus, Dengue virus and Chikungunya virus.</AbstractText><CopyrightInformation>&#xa9; 2020 Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Shruti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Achyut</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manvati</LastName><ForeName>Siddharth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Coumarin</Keyword><Keyword MajorTopicYN="N">Health sciences</Keyword><Keyword MajorTopicYN="N">Inhibitor</Keyword><Keyword MajorTopicYN="N">Mechanism</Keyword><Keyword MajorTopicYN="N">Microbiology</Keyword><Keyword MajorTopicYN="N">Natural product</Keyword><Keyword MajorTopicYN="N">Pharmaceutical science</Keyword><Keyword MajorTopicYN="N">Pharmacology</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">Viral replication</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32042967</ArticleId><ArticleId IdType="pmc">PMC7002824</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2020.e03217</ArticleId><ArticleId IdType="pii">S2405-8440(20)30062-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sagar S., Kaur M., Minneman K.P. Antiviral lead compounds from marine sponges. Mar. Drugs. 2010:2619&#x2013;2638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992996</ArticleId><ArticleId IdType="pubmed">21116410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye N., Chen H., Wold E.A., Shi P., Zhou J. Therapeutic potential of spirooxindoles as antiviral agents. ACS Infect. Dis. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5417367</ArticleId><ArticleId IdType="pubmed">27627626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru J., Kapoor M., Tsay S., Lin C., Chu K. Benzouracil &#x2013; coumarin &#x2013; arene conjugates as inhibiting agents for chikungunya virus. Antivir. Res. 2015:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25839734</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandarage U.K., Clark M.P., Perola E., Gao H., Jacobs M.D., Tsai A. Novel 2-substituted 7-azaindole and 7-azaindazole analogues as potential anti-viral agents for the treatment of influenza. ACS Med. Chem. Lett. 2017;8(2):261&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5304303</ArticleId><ArticleId IdType="pubmed">28197323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagno V., Donalisio M., Civra A., Cagliero C., Rubiolo P., Lembo D. In vitro evaluation of the antiviral properties of Shilajit and investigation of its mechanisms of action. J.&#xa0;Ethnopharmacol. 2015;166:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">25792012</ArticleId></ArticleIdList></Reference><Reference><Citation>V Vernekar S.K., Tang J., Wu B., Huber A.D., Casey M.C., Myshakina N., Wilson D.J., Kankanala J., Kirby K.A., Parniak M.A., Sara S.G., Wang Z. Double-winged 3 - hydroxypyrimidine-2,4-diones: potent and selective inhibition against HIV - 1 RNase H with signi fi cant antiviral activity. J.&#xa0;Med. Chem. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526604</ArticleId><ArticleId IdType="pubmed">28525279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy D.A., Read A.F. Why does drug resistance readily evolve but vaccine resistance does not? Proc. R. Soc. B: Biol. Sci. 2017;284:20162562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378080</ArticleId><ArticleId IdType="pubmed">28356449</ArticleId></ArticleIdList></Reference><Reference><Citation>Field H.J., Wainberg M.A. Antiviral drug development. Future Virol. 2011;6(5):545&#x2013;547.</Citation></Reference><Reference><Citation>De Clercq E. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 2016;29:695&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978613</ArticleId><ArticleId IdType="pubmed">27281742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pour P.M., Fakhri S., Asgary S., Farzaei M.H., Echeverr&#xed;a J. The signaling pathways, and therapeutic targets of antiviral agents: focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front. Pharmacol. 2019;10:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6856223</ArticleId><ArticleId IdType="pubmed">31787892</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycol V., Kotwal G.J., Longum P. Natural Antivirals against Human Viruses Bitter melon. Virol. Mycol. 2014;3:3&#x2013;5.</Citation></Reference><Reference><Citation>Lin L.T., Hsu W.C., Lin C.C. Antiviral natural products and herbal medicines. J.&#xa0;Tradit. Complement. Med. 2014;4:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4032839</ArticleId><ArticleId IdType="pubmed">24872930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D., Hsu W. Antiviral potential of curcumin. J.&#xa0;Funct. Foods. 2018;40:692&#x2013;699.</Citation></Reference><Reference><Citation>Kannan S., Kolandaivel P. Antiviral potential of natural compounds against influenza virus hemagglutinin. Comput. Biol. Chem. 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">29149637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.Y., Huang S.C., Zhang Y., Lai Z.R., Kung S.H., Chang Y.S., Lin C.W. Antiviral ability of Kalanchoe gracilis leaf extract against Enterovirus 71 and coxsackievirus A16, Evidence-Based Complement. Altern. Med. 2012;2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361180</ArticleId><ArticleId IdType="pubmed">22666293</ArticleId></ArticleIdList></Reference><Reference><Citation>Riveiro M.E., De Kimpe N., Moglioni A., V&#xe1;zquez R., Monczor F., Shayo C., Davio C. Coumarins: old compounds with novel promising therapeutic perspectives. Curr. Med. Chem. 2010:1325&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">20166938</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Gao Q., Yuan S., Wang L., Altmeyer R., Lan K., Yin F., Zou G. Characterization of three small molecule inhibitors of enterovirus 71 identified from screening of a library of natural products. Antivir. Res. 2017;143:85&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28412182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan M.Z., Osman H., Ali M.A., Ahsan M.J. Therapeutic potential of coumarins as antiviral agents. Eur. J. Med. Chem. 2016 AC SC.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7115672</ArticleId><ArticleId IdType="pubmed">27484512</ArticleId></ArticleIdList></Reference><Reference><Citation>Venugopala K.N., Rashmi V., Odhav B. Review on natural coumarin lead compounds for their pharmacological activity. BioMed Res. Int. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622347</ArticleId><ArticleId IdType="pubmed">23586066</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanachi A., Leonetti F., Pisani L., Catto M., Carotti A. Coumarin: a natural, privileged and versatile scaffold for bioactive compounds. Molecules. 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6017103</ArticleId><ArticleId IdType="pubmed">29382051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarker S.D., Nahar L. Progress in the chemistry of naturally occurring coumarins. Prog. Chem. Org. Nat. Prod. 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">28762091</ArticleId></ArticleIdList></Reference><Reference><Citation>PERKIN W.H. On the artificial production of coumarin and formation of its homologues. J.&#xa0;Chem. Soc. 1868:53&#x2013;63. A. Production, By. F.R.S. IT.</Citation></Reference><Reference><Citation>Jadhav N.H., Sakate S.S., Rasal N.K., Shinde D.R., Pawar R.A. Heterogeneously catalyzed Pechmann condensation employing the tailored Zn0. 925Ti0. 075O NPs: synthesis of coumarin. ACS Omega. 2019;4:8522&#x2013;8527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6648791</ArticleId><ArticleId IdType="pubmed">31459942</ArticleId></ArticleIdList></Reference><Reference><Citation>Desimone R.W., Currie K.S., Mitchell S.A., Darrow J.W., Pippin D.A. Privileged Structures&#xa0;;: applications in drug discovery. Comb. Chem. High Throughput Screen. 2004:473&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">15320713</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Jiang J. Pharmacological and nutritional effects of natural coumarins and their structure-activity relationships. Mol. Nutr. Food Res. 2018:1&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">29750855</ArticleId></ArticleIdList></Reference><Reference><Citation>Laila U., Akram M., Ali M., Mehmmod A., Naheed H., Imtiaz A., Tahir M., Owais A., Naveed G., Muhammad M., Naheed R., Shaheen G., Ullah Q., Zahid R. Role of medicinal plants in HIV/AIDS therapy. Clin. Exp. Pharmacol. Physiol. 2019:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikrishna D. A&#xa0;review on pharmacological properties of coumarins. Mini Rev. Med. Chem. 2017 Scanned by CamScanner.</Citation><ArticleIdList><ArticleId IdType="pubmed">27488585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo E., Taura M., Matsuda K., Shimamoto M., Kariya R., Goto H., Hattori S., Kimura S., Okada S. Inhibition of HIV-1 replication by a tricyclic coumarin GUT-70 in acutely and chronically infected cells. Bioorg. Med. Chem. Lett. 2013;23:606&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">23290051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandmann L., Schulte B., Manns M.P., Maasoumy B. Treatment of chronic hepatitis C: efficacy, side effects and complications. Vis. Med. 2019;35:161&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6616049</ArticleId><ArticleId IdType="pubmed">31367613</ArticleId></ArticleIdList></Reference><Reference><Citation>Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1860034</ArticleId><ArticleId IdType="pubmed">16905701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly T., Permanente K., California N., Dermatol A.A., Tinea M.S., Ges D.D., Management G.R., Cosmet C., Dermatol I., Sc H., Tinea B.J., Js M., Infect E., Lm D., Bg R., Kh R., Control I., Epidemiol H., Pc S., Rc S., Journal B. Cutaneous side-effects of antihepatitis C treatment;: the U. K. experience. Br. J. Dermatol. 2014:2014&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">24975744</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B. Drug pricing &amp; challenges to hepatitis C treatment access. J.&#xa0;Heal. Biomed. Law. 2018;14:265&#x2013;283. http://www.ncbi.nlm.nih.gov/pubmed/30258323%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6152913</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6152913</ArticleId><ArticleId IdType="pubmed">30258323</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsay S., Lin S., Huang W., Hsu M., Hwang K.C., Lin C., Horng J., Chen I., Hwu J.R., Shieh F., Leyssen P., Neyts J. Synthesis and Structure-activity relationships of imidazole-coumarin conjugates against hepatitis C virus. Molecules. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6273635</ArticleId><ArticleId IdType="pubmed">26901180</ArticleId></ArticleIdList></Reference><Reference><Citation>Rino Y., Ohkawa S., Shimizu A., Tamai S., Miyakawa K., Aoki H., Imada T., Shindo K., Okamoto N., Totsuka S. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer. 1999:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440686</ArticleId></ArticleIdList></Reference><Reference><Citation>Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma. Intervirology. 2000:20&#x2013;26. O. Paper. 0815.</Citation><ArticleIdList><ArticleId IdType="pubmed">10773734</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T., Kajino K., Hino O. Hepatoprotective drugs for the treatment of virus-induced chronic hepatitis;: from hypercarcinogenic state to hypocarcinogenic state. Jpn. J. Pharmacol. 2001;180:177&#x2013;180. REVIEW &#x2014; Current Perspective.</Citation><ArticleIdList><ArticleId IdType="pubmed">11885965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru J., Singha R., Ching S., Hsiung Y., Das A.R., Vliegen I., De Clercq E., Neyts J. Synthesis of new benzimidazole &#x2013; coumarin conjugates as anti-hepatitis C virus agents. Antivir. Res. 2008;77:157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">17977606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu M., Shieh F., Lin C., Hwang K.C. Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus. Eur. J. Med. Chem. 2013 SC.</Citation><ArticleIdList><ArticleId IdType="pubmed">23501114</ArticleId></ArticleIdList></Reference><Reference><Citation>Neyts J., De Clercq E., Singha R., Chang Y.H., Das A.R., Chakraborty S.K. Structure - activity relationship of new anti-hepatitis C virus agents: heterobicycle - coumarin conjugates. J.&#xa0;Med. Chem. 2009:1486&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pubmed">19193060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwu J.R., Lin S., Tsay S., De Clercq E., Leyssen P., Neyts J. Coumarin - purine ribofuranoside conjugates as new agents against hepatitis C virus. J.&#xa0;Med. Chem. 2011:2114&#x2013;2126.</Citation><ArticleIdList><ArticleId IdType="pubmed">21375337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols D.B., Le R.A.C., Basu A., Chudayeu M., De F P., Moraes D., Talele T.T., Paulo R.R., Kaushik-basu N. Evaluation of coumarin and neoflavone derivatives as HCV NS 5 B polymerase inhibitors. Chem. Biol. Drug Des. 2013;81(5):607&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">23311976</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H., Chen W., Lee J., Yang S., Tzeng C., Lin Y., Yang S. Novel anilinocoumarin derivatives as agents against hepatitis C virus by the induction of IFN-mediated antiviral responses. Org. Biomol. Chem. 2013:1858&#x2013;1866.</Citation><ArticleIdList><ArticleId IdType="pubmed">23377187</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.C., Wu P.L., Wu T.S. Two coumarins from the root bark of Clausena excavata. Phytochemistry. 1997;44(1):179&#x2013;181.</Citation></Reference><Reference><Citation>Su C., Farn S., Miem C., Damu A.G., Kuo T., Chiang P., Bastow K.F., Lee K., Wu T. Bioorganic &amp; Medicinal Chemistry Anti-HBV and cytotoxic activities of pyranocoumarin derivatives. Bioorg. Med. Chem. 2009;17:6137&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635670</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore J.P., Stevenson M. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. 2000;1:40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">11413488</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastav V.K., Tiwari M., Zhang X., Yao X.J. Synthesis and antiretroviral activity of 6-Acetyl-coumarin derivatives against HIV-1 infection. Indian J. Pharm. Sci. 2018;80:108&#x2013;117.</Citation></Reference><Reference><Citation>Srivastav V.K., Tiwari M. QSAR and docking studies of coumarin derivatives as potent HIV-1 integrase inhibitors. Arab. J. Chem. 2017;10:S1081&#x2013;S1094.</Citation></Reference><Reference><Citation>Jesumoroti O.J., Mnkandhla D., Isaacs M., Hoppe H.C., Klein R. Evaluation of novel N&#x2032;-(3-hydroxybenzoyl)-2-oxo-2H-chromene-3-carbohydrazide derivatives as potential HIV-1 integrase inhibitors. MedChemComm. 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350760</ArticleId><ArticleId IdType="pubmed">30774857</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimi Z., Safakish M., Hajimahdi Z., Soleymani S. Design, synthesis, molecular modeling, in silico ADME studies and anti- HIV-1 assay of new diazocoumarin derivatives. Iran. J. Pharm. Res. (IJPR): 2018;17:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447871</ArticleId><ArticleId IdType="pubmed">31011343</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C.-C., Mouscadet J.-F., Tsai H.-J., Liu C.-T., Hsu L.-Y. Synthesis and HIV-1 integrase inhibition of novel bis- or tetra-coumarin analogues. Chem. Pharm. Bull. 2007;55:1740&#x2013;1743. (Tokyo)</Citation><ArticleIdList><ArticleId IdType="pubmed">18057750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunney E.A., Hagen S.E., Domagala J.M., Humblet C., Kosinski J., Tait B.D., Warmus J.S., Wilson M., Ferguson D., Hupe D., Tummino P.J., Baldwin E.T., Bhat T.N., Liu B., Ericksod J.U.T. A&#xa0;novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs. J.&#xa0;Med. Chem. 1994:2664&#x2013;2677.</Citation><ArticleIdList><ArticleId IdType="pubmed">8064795</ArticleId></ArticleIdList></Reference><Reference><Citation>Olomola T.O., Klein R., Mautsa N., Sayed Y., Kaye P.T. Bioorganic &amp; Medicinal Chemistry Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors. Bioorg. Med. Chem. 2013:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23415084</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda K., Hattori S., Kariya R., Komizu Y., Kudo E., Goto H., Taura M., Ueoka R., Kimura S., Okada S. Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity. Biochem. Biophys. Res. Commun. 2015;457:288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">25576356</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada S., Yusa K., Monde K., Akaike T., Maeda Y. Influence of membrane fluidity on human immunodeficiency virus type 1 entry. Biochem. Biophys. Res. Commun. 2005;329:480&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">15737612</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmedo D.A., Luis L., Olmo E., Bedoya L.M., Mu&#xf1;oz E., Feliciano A.S., Gupta M.P. Neoflavonoids as inhibitors of HIV-1 replication by targeting the Tat and NF- &#x3ba; B pathways. Molecules. 2017:2&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155902</ArticleId><ArticleId IdType="pubmed">28218730</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;rquez N., Sancho R., Bedoya L.M., Alcam&#xed; J., L&#xf3;pez-P&#xe9;rez J.L., San Feliciano A., Fiebich B.L., Mu&#xf1;oz E. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-&#x3ba;B pathway. Antivir. Res. 2005;66:137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">15911030</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zeng H., Wang P., Lin L., Liu L., Zhen P., Fu Y., Lu P., Zhu H. Reactivation of latent HIV-1 in latently infected cells by coumarin compounds: hymecromone and scoparone. Curr. HIV Res. 2016:484&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">27697031</ArticleId></ArticleIdList></Reference><Reference><Citation>Spanakis N., Pitiriga V. A&#xa0;review of neuraminidase inhibitor susceptibility in influenza strains. Expert Rev. Anti-infect. Ther. 2014:1325&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pubmed">25301229</ArticleId></ArticleIdList></Reference><Reference><Citation>Khomenko T.M., V Zarubaev V., Orshanskaya I.R., Kadyrova R.A., Sannikova V.A., V Korchagina D., Volcho K.P., Salakhutdinov N.F. Bioorganic &amp; medicinal chemistry letters anti-influenza activity of monoterpene-containing substituted coumarins. Bioorg. Med. Chem. Lett. 2017;27:2920&#x2013;2925.</Citation><ArticleIdList><ArticleId IdType="pubmed">28501512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Yan W., Chen Q., Huang W., Yang Z., Li X., Wang X. Inhibition viral RNP and anti-in fl ammatory activity of coumarins against in fl uenza virus. Biomed. Pharmacother. 2017;87:583&#x2013;588. ScienceDirect.</Citation><ArticleIdList><ArticleId IdType="pubmed">28081470</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W.E.N., Zheng C., He J., Zhang W., Huang X.I.N.A.N. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Int. J. Mol. Med. 2018:2776&#x2013;2792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192727</ArticleId><ArticleId IdType="pubmed">30226535</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman H., Yusufzai S.K., Khan M.S., Razik B.M.A., Sulaiman O., Mohamad S., Gansau J.A., Ezzat M.O., Parumasivam T., Hassan M.Z. New thiazolyl-coumarin hybrids: design, synthesis, characterization, X-ray crystal structure, antibacterial and antiviral evaluation. J.&#xa0;Mol. Struct. 2018 AC.</Citation></Reference><Reference><Citation>Pavurala S., Vaarla K., Kesharwani R., Liekens S., Vedula R.R. Bis coumarinyl bis triazolothiadiazinyl ethane derivatives: synthesis, antiviral activity evaluation, and molecular docking studies ARTICLE HISTORY. Synth. Commun. 2018;48:1494&#x2013;1503.</Citation></Reference><Reference><Citation>Bae Y., Hoon J., Park S., Sun J., Rho M., Bae K., Hun K., Song W. Bioorganic &amp; Medicinal Chemistry Letters Inhibition of neuraminidase activity by polyphenol compounds isolated from the roots of Glycyrrhiza uralensis. Bioorg. Med. Chem. Lett. 2010;20:971&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">20064716</ArticleId></ArticleIdList></Reference><Reference><Citation>Escuret V., Frobert E., Bouscambert-duchamp M., Sabatier M., Grog I., Valette M., Lina B., Morfin F., Ferraris O. Detection of human influenza A ( H1N1 ) and B strains with reduced sensitivity to neuraminidase inhibitors. J.&#xa0;Clin. Virol. 2008;41:25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">18055253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizzarri B.M., Botta L., Capecchi E., Celestino I., Checconi P., Palamara A.T., Nencioni L. Regioselective IBX-mediated synthesis of coumarin derivatives with antioxidant and anti-in fl uenza activities. J.&#xa0;Nat. Prod. 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">29236486</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-calder&#xf3;n C., Mesa-castro C., Robledo S., G&#xf3;mez S., Bolivar-avila S. Antiviral effect of compounds derived from the seeds of Mammea americana and Tabernaemontana cymosa on Dengue and Chikungunya virus infections. BMC Complement Altern. Med. 2017:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241984</ArticleId><ArticleId IdType="pubmed">28100218</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel P., Schiering N., Arcy A.D., Renatus M., Kroemer M., Lim S.P., Yin Z., Keller T.H., Vasudevan S.G., Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 2006;13:2005&#x2013;2006.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532006</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusufzai S.K., Osman H., Khan M.S., Razik B.M.A. 4 - thiazolidinone coumarin derivatives as two - component NS2B/NS3 DENV flavivirus serine protease inhibitors: synthesis, molecular docking, biological evaluation and structure &#x2013; activity relationship studies. Chem. Cent. J. 2018:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997609</ArticleId><ArticleId IdType="pubmed">29896651</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulerie P., Maciuk A., Lebouvier N., Hnawia E., Guillemot J., Canard B., Figad&#xe8;re B., Nour M. Phytochemical study of Myrtopsis corymbosa, perspectives for Anti-dengue natural compound research. Rec. Nat. Prod. 2013;3:250&#x2013;253.</Citation></Reference><Reference><Citation>Zainal N., Chang C., Cheng Y., Wu Y. Resveratrol treatment reveals a novel role for HMGB1 in regulation of the type 1 interferon response in dengue virus infection. Nat. Publ. Gr. 2017:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316936</ArticleId><ArticleId IdType="pubmed">28216632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru J., Huang W., Lin S., Tan K. European Journal of Medicinal Chemistry Chikungunya virus inhibition by synthetic coumarin e guanosine conjugates. Eur. J. Med. Chem. 2019;166:136&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">30703657</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H., Schafer A., Soloveva V., Gharaibeh D., Kenny T., Zamani R., Bavari S., Peet N.P., Rong L. Identification of a coumarin-based antihistamine as an anti-filoviral entry inhibitor. Antivir. Res. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666694</ArticleId><ArticleId IdType="pubmed">28645623</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Liu L., Feng C., Hu Y., Chen C., Wang G., Zhu B. Fish and Shell fi sh Immunology Synthesis and antiviral activity of a new coumarin derivative against spring viraemia of carp virus. Fish Shellfish Immunol. 2018;81:57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">29981474</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G., Wang C., Wang H., Zhu L., Zhang H., Wang Y. Antiviral e ffi ciency of a coumarin derivative on spring viremia of carp virus in vivo. Virus Res. 2019;268:11&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">31095989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Liu L., Shen Y., Hu Y., Ling F., Wang X., Zhu B. PT key laboratory of applied marine biotechnology of ministry of education, ningbo. Cell. Signal. 2018</Citation></Reference><Reference><Citation>Liu L., Hu Y., Lu J., Wang G. An imidazole coumarin derivative enhances the antiviral response to spring viremia of carp virus infection in zebrafish Authors: SC. Virus Res. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">30658072</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens D.M., Taubenberger J.K., Harvey H.A., Memoli M.J. The 1918 influenza pandemic: lessons for 2009 and the future. Crit. Care Med. 2010;38:e10&#x2013;e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3180813</ArticleId><ArticleId IdType="pubmed">20048675</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawood F.S., Iuliano A.D., Reed C., Meltzer M.I., Shay D.K., Cheng P.Y., Bandaranayake D., Breiman R.F., Brooks W.A., Buchy P., Feikin D.R. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 2012;12(9):687&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">22738893</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . World Health Organization; Geneva, Switzerland: 2019. Cumulative Number of Confirmed Human Cases for Avian Influenza A (H5N1) Reported to WHO, 2003-2019.</Citation></Reference><Reference><Citation>World Health Organization . WHO News release; 2017. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year.</Citation></Reference><Reference><Citation>WHO, W . World Health Organization; Geneva: 2017. Global Hepatitis Report 2017.</Citation></Reference><Reference><Citation>Global, H. I. V. AIDS Statistics&#x2013;2018 Fact Sheet. UNAIDS; 2019.</Citation></Reference><Reference><Citation>World Health Organization . 2018. Global Strategy for Dengue Prevention and Control: 2012&#x2013;2020.http://www.who.int/denguecontrol/9789241504034/en/ Avilable from: Accessed, 18.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>